Teva’s EpiPen generic retails for same price as Mylan’s own

pharmafile | November 28, 2018 | News story | Research and Development, Sales and Marketing Mylan, Teva, epipen, pharma 

Israeli generics firm Teva has revealed the price tag of its generic version of Mylan’s EpiPen epinephrine auto-injector, and, at $300 wholesale for a pack of two, it comes in at exactly the same point as Mylan’s own long-anticipated generic version.

The announcement means that patients have two alternative options for the therapy, which both come in at less than half the cost of the branded product.

The recent shortage of EpiPens, which Mylan blames on manufacturing issues at a plant run by Pfizer, has compounded the need for cheaper, generic versions.  With the launch of the Teva’s product, it is now available in the US, albeit with limited supply; the company appeared unable to confirm how many it had released into the market, noting that the product is complex in nature and manufacturing only began in August following its FDA approval.  

According to Teva, additional supply is inbound next year, as well as a generic version of Mylan’s EpiPen Jr, which carries a lower dose.

Matt Fellows

Related Content

Pfizer to pay $345 million in EpiPen lawsuit

Pfizer has reached a $345 million settlement over consumer claims they overpaid for EpiPens as …

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

Latest content